Evidence map›Paper›PMID 34328634›Full record

ArticleInternational journal of hematology2021

Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapy.

Shinichi Kako, Fumihiko Hayakawa, Kiyotoshi Imai, Junji Tanaka, Shuichi Mizuta, Satoshi Nishiwaki, Heiwa Kanamori, Junichi Mukae, Yukiyasu Ozawa, Tadakazu Kondo and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 20 institutions in 1 country.

Shinichi KakoDivision of Hematology, Department of Internal Medicine, Jichi Medical University Saitama Medical Center, 1-847 Amanuma, Omiya-ku, Saitama, Saitama, 330-8503, Japan. shinichikako@asahi-net.email.ne.jp.ORCID http://orcid.org/0000-0002-2635-3395
Fumihiko HayakawaDepartment of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kiyotoshi ImaiDepartment of Hematology, Otaru General Hospital, Otaru, Japan.
Junji TanakaDepartment of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
Shuichi MizutaDepartment of Immunology and Hematology, Kanazawa Medical University, Ishikawa, Japan.
Satoshi NishiwakiDepartment of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
Heiwa KanamoriDepartment of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
Junichi MukaeHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Yukiyasu OzawaDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Tadakazu KondoDepartment of Hematology, Kyoto University Hospital, Kyoto, Japan.
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Tatsuo IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Shuichi OtaDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Yoshinori TanakaThird Department of Internal Medicine, Yamaguchi University School of Medicine, Yamaguchi, Japan.
Tohru MurayamaDepartment of Hematology, Hyogo Cancer Center, Akashi, Japan.
Shingo KurahashiDivision of Hematology and Oncology, Toyohashi Municipal Hospital, Aichi, Japan.
Toru SakuraLeukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan.
Noriko UsuiDivision of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Shigeki OhtakeKanazawa University, Kanazawa, Japan.
Hitoshi KiyoiDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Itaru MatsumuraDepartment of Hematology/Rheumatology, Faculty of Medicine, Kindai University, Osakasayama, Japan.
Yasushi MiyazakiAtomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Yoshiko AtsutaDepartment of Healthcare Administration, Nagoya University, Nagoya, Japan.
Nagoya University · JPGunma Saiseikai Maebashi Hospital · JPHiroshima University · JPHyogo Prefectural Cancer Center · JPJichi Medical University · JPJikei University School of Medicine · JPKanagawa Prefectural Hospital Organization · JPKanazawa Medical University · JPKanazawa University · JPKindai University · JPKyoto University Hospital · JPNagasaki University · JPNagoya University Hospital · JPOtaru Municipal Hospital · JPSapporo Hokuyu Hospital · JPThe Japanese Data Center for Hematopoietic Cell Transplantation · JPTokyo Metropolitan Komagome Hospital · JPTokyo Women's Medical University · JPToyohashi Municipal Hospital · JPYamaguchi University · JP

Funding

japan agency for medical research and development 19ek0510023h0002japan agency for medical research and development JP19ck0106331
6 · The paper itself

Abstract

The optimal treatment for Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) has not been established in the high-intensity chemotherapy era. The outcomes of patients with Ph-negative ALL who underwent allogeneic hematopoietic stem cell transplantation (HSCT) from a human leukocyte antigen-matched related or unrelated donor in CR1 (HSCT-MRD group and HSCT-MUD group) were obtained from a Japanese registry database. Patients aged 16-24 years and 25-65 years were analyzed separately, and their outcomes were compared to those of patients who continued high-intensity chemotherapy in CR1 in studies (202U group and 202O group) by the Japan Adult Leukemia Study Group (JALSG). In the HSCT-MRD group, patients younger than 25 years had lower overall survival (OS) than the 202U group, presumably due to the higher non-relapse mortality (NRM) in the HSCT-MRD group. Patients 25 years and older had similar OS to the 202O group. The lower relapse rate was counterbalanced by higher NRM in the HSCT-MRD group. In the HSCT-MUD group, patients in both age groups had similar OS to their corresponding groups in the JALSG studies. In conclusion, high-intensity chemotherapy may change the role of HSCT for Ph-negative ALL.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsClinical Decision-MakingCombined Modality TherapyDisease ManagementFemaleHematopoietic Stem Cell TransplantationHistocompatibility TestingHumansMaleMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaPrognosisRemission InductionAllogeneic hematopoietic stem cell transplantationHigh-intensity chemotherapyPhiladelphia chromosome-negative acute lymphoblastic leukemia

Identifiers

PMID34328634
OpenAlexW3186591940

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.